Latest: AVM Biotechnology was just interviewed by Seattle’s KOMO 4 News about our COVID-19 treatment, AVM0703, that could be better than Oxford’s released trial results. Watch now!

Transforming the Future of Immunotherapy with our Global Leadership Team

Executive Board

Founder and CEO

Theresa A. Deisher, Ph.D.

Doctoral degree in Molecular and Cellular Biology from Stanford University School of Medicine. Holds more than 47 issued US/EU/Japan patents and 3 discoveries in clinical trials. Over 30 years of pharmaceutical leadership experience including Genentech, Repligen, ZymoGenetics, Immunex, and Amgen.

Board Member

Manon Cox, Ph.D., MBA

Doctorate from the University of Wageningen. MBA with distinction from the University of Nyenrode and the University of Rochester, NY. Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands. Co-founder of NextWaveBio. Led the development of Flublok®, the only FDA approved recombinant influenza vaccine while serving as President and Chief Executive Officer of Protein Sciences Corporation.

Board Member

Gary Grohmann, B. Sc. (Hons), Ph.D, FASM

Doctorate from University of Sydney, Department of Infectious Diseases. Bachelor of Science University of New South Wales, Department of Microbiology and Immunology. Director of Immunisation Coalition and Director/Founder of Environmental Pathogens. Former Director of Immunobiology and WHO ERL at the TGA, and former WHO Advisor and Consultant. 

Board Member

Michael Bernard, J.D.

Mr. Bernard received his B.S.B.A. and J.D. from Creighton University. He currently serves as Chief Tax Officer at Vertex, Inc., is the Chairman of TEI’s National Communications and Technology Committee, and former US Chief Tax Counsel to Microsoft.

Advisory Board

Scientific & Clinical Advisor

William Matsui, M.D.

Deputy Director Livestrong Cancer Institutes, Professor Department of Oncology, Dell Medical School, received his AB in Biochemistry from Harvard and M.D. from the University of California SanFrancisco. Dr. Matsui has carried out research throughout his career making several key discoveries in clinical oncology.

Scientific & Clinical Advisor

John Harlan, M.D.

Professor Emeritus of Medicine at the University of Washington, former  Head of the Division of Hematology at UW and Chief of Hematology-Oncology at Harborview Medical Center. Dr. Harlan has over 200 publications, is designated as a ‘Highly Cited’ researcher in Immunology, and has been selected as “Best Doctors in America”.

Scientific & Clinical Advisor

Frank Buttgereit, M.D.

Senior Consultant and Deputy Director, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin. Professor of Rheumatology, Charité Universitätsmedizin Berlin.   

Scientific & Clinical Advisor

Gordon Roble, D.V.M.

Dr. Roble is Director of Comparative Medicine at Fred Hutchinson Cancer Research Center. He received his MBA from NYU, his Doctor of Veterinary Medicine from Tufts University, and BA in Biology from Swarthmore College.

Scientific & Clinical Advisor

Gustavo Mahler, Ph.D.

Former CEO AGC Biologics. Dr. Mahler received his Ph.D. in Biochemistry from the University of Buenos Aires, MBA from the University UNED of Madrid, and an Executive Certification in Management from MIT Sloan.

Scientific & Clinical Advisor, CMO - Compassionate Use Program

Edward Loniewski, D.O.

Michigan State University, College of Osteopathic Medicine. University of Chicago Fellowship Arthritis & Adult Reconstruction. Founder Cellular Healing.

Administrative Team

President and CEO

Michael Anderson

Mr. Anderson has held key management and executive positions in the highly regulated banking industry and has a long history of building and leading strong teams and working effectively in government-regulated environments.

VP of Investor Relations

Terry Kopp

Terrence (Terry) Kopp had a successful 27-year history in marketing and sales with a major programming network in cable TV and has served in investor relations leadership for AVM Biotechnology since 2014, including leading series B, C, and D raises.

Director of IT

Andrew A. Aldwell

Mr. Aldwell has over ten years of experience working in and around the IT sector, as well as a strong background in software engineering and web development.  He has received a Bachelor’s degree in Computer Science and Real-Time Interactive Simulation from DigiPen Institute of Technology.

Director of Communications & Public Relations

Jena Dalpez

Ms. Dalpez has an extensive background in communications, sales, marketing, contract management & negotiation, event planning, financial management, project & product management, and community outreach in the health insurance field as well as in the nonprofit sector.

Business Analyst

Shruti Haridas

Ms. Haridas received her Master's degree in Information Systems Management from Seattle Pacific University and also has a Bachelor’s degree in Biotechnology Engineering. She previously worked as a Data Analyst and as an Industry Analyst.

Research Team

Director of Lab Research

Peter Jarzyna, Ph.D.

Received his Ph.D. in Pharmacy (tumor biology/imaging) from the University of Regensburg in Germany. He gained international experience in the field of preclinical cancer/imaging research and has successfully led many projects.

Senior Research Scientist

Yumna Zahid, M.S.

Ms. Zahid has experience in the fields of Stem Cell Biology and Immunology. She has previously worked in cell therapy research for Cystic Fibrosis and fibrosing diseases such as Idiopathic Pulmonary Fibrosis.

Senior Research Scientist

Vaishnavi Parthasarathy, M.S.

Ms. Parthasarathy has over 8 years of experience in Flow cytometry and polyclonal antibody production. She has previously worked in the Flow cytometry core focusing on HIV research in Boston, MA. She completed her undergraduate in Biotechnology from India and went on to pursue her graduate studies in the U.S, where she completed her M.S. in Biology at the University of Texas at San Antonio.

Lab Manager

Stephanie Lee-Diaz

Research Scientist

Kendra Poulin

Research Scientist

Colleen Rylatt

The answer to our nation’s call